FDA unveils new pilot program; Sage finds a buyer; Eli Lilly to acquire Verve; and morenews2025-06-21T10:00:26+00:00June 21st, 2025|Endpoints News|
RFK removes all ACIP members, names new ones; National Resilience to close six sites; Deals and financing recap of the weeknews2025-06-14T10:00:04+00:00June 14th, 2025|Endpoints News|
Highlights from #ASCO25; Biotech’s icy market; Sanofi’s $9B acquisition; and morenews2025-06-07T10:00:28+00:00June 7th, 2025|Endpoints News|
Patient dies in Rocket gene therapy trial; Lilly’s $1B deal for a non-opioid pain biotech; A new dawn for psychedelics?; and morenews2025-05-31T10:00:19+00:00May 31st, 2025|Endpoints News|
Analyzing the Endpoints 100; ‘Most favored nation’ targets revealed; Biotech slump makes leases a liability; and morenews2025-05-24T10:00:30+00:00May 24th, 2025|Endpoints News|
What we know about ‘most favored nation’; GSK’s $1.2B MASH deal; Bayer details staff cuts; and morenews2025-05-17T10:00:13+00:00May 17th, 2025|Endpoints News|
Makary names Vinay Prasad CBER chief; Q1 earnings report; More on “Most Favored Nations”; and morenews2025-05-10T10:00:49+00:00May 10th, 2025|Endpoints News|
Earnings season continues; FDA delays PDUFA date; AACR recap; and morenews2025-05-03T10:00:41+00:00May 3rd, 2025|Endpoints News|
Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and morenews2025-04-26T10:00:25+00:00April 26th, 2025|Endpoints News|
Trump’s executive order on drug pricing; Pfizer drops oral obesity drug; Seed rounds at their lowest in years; and morenews2025-04-19T10:00:15+00:00April 19th, 2025|Endpoints News|
